The manuscript was developed by the WBDR Steering Committee, WBDR staff and participating hemophilia healthcare providers. With findings gleaned from over 10,000 patients across 40 countries, the publication is a crucial roadmap for understanding and addressing the unique challenges faced by PWH. This type of research is useful for informing evidence-based advocacy efforts, clinical practice, healthcare policies, and for improving the quality of care for people with inherited bleeding disorders.
The WBDR team expresses their sincere appreciation to all HTC teams, healthcare providers, and patients for their commitment and contributions to the WBDR. They have not only fueled this meaningful research, but have also paved the way for better understanding, advocacy, and care in the field.
To find out more, read the manuscript here. To learn more about the World Bleeding Disorders Registry (WBDR), please click here.
The WBDR’s evolution and expansion has been made possible through the collaborative efforts of visionary partners Sobi and Takeda, as well as collaborating partners including Grifols, F. Hoffman-La Roche, Pfizer, and Sanofi.